Intech Investment Management LLC Sells 10,960 Shares of Viridian Therapeutics, Inc. $VRDN

Intech Investment Management LLC cut its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 17.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 50,668 shares of the company’s stock after selling 10,960 shares during the quarter. Intech Investment Management LLC’s holdings in Viridian Therapeutics were worth $708,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of VRDN. Paradigm Biocapital Advisors LP lifted its position in Viridian Therapeutics by 15.1% in the first quarter. Paradigm Biocapital Advisors LP now owns 2,095,079 shares of the company’s stock valued at $28,242,000 after purchasing an additional 275,000 shares during the last quarter. Maverick Capital Ltd. raised its holdings in Viridian Therapeutics by 0.4% during the 1st quarter. Maverick Capital Ltd. now owns 2,061,274 shares of the company’s stock valued at $27,786,000 after buying an additional 7,368 shares during the last quarter. Geode Capital Management LLC boosted its position in Viridian Therapeutics by 1.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,740,614 shares of the company’s stock valued at $24,337,000 after buying an additional 20,089 shares during the period. Goldman Sachs Group Inc. grew its holdings in Viridian Therapeutics by 33.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after acquiring an additional 310,998 shares during the last quarter. Finally, Candriam S.C.A. increased its position in shares of Viridian Therapeutics by 20.4% in the first quarter. Candriam S.C.A. now owns 880,430 shares of the company’s stock valued at $11,868,000 after acquiring an additional 149,209 shares during the period.

Insider Activity at Viridian Therapeutics

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 454,545 shares of Viridian Therapeutics stock in a transaction dated Thursday, October 23rd. The shares were purchased at an average cost of $22.00 per share, with a total value of $9,999,990.00. Following the transaction, the director directly owned 3,914,458 shares of the company’s stock, valued at $86,118,076. This represents a 13.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.58% of the company’s stock.

Viridian Therapeutics Stock Up 1.0%

Shares of NASDAQ:VRDN opened at $31.72 on Thursday. The firm has a market capitalization of $3.03 billion, a P/E ratio of -8.28 and a beta of 0.72. The company has a debt-to-equity ratio of 0.04, a quick ratio of 11.01 and a current ratio of 11.01. The stock has a 50 day moving average price of $24.01 and a 200-day moving average price of $19.03. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $32.54.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.48. The company had revenue of $70.57 million for the quarter, compared to analyst estimates of $16.21 million. Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The firm’s quarterly revenue was up 81993.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on VRDN shares. Royal Bank Of Canada increased their target price on shares of Viridian Therapeutics from $41.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Wall Street Zen raised Viridian Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. The Goldman Sachs Group reiterated a “buy” rating and issued a $40.00 price objective on shares of Viridian Therapeutics in a research report on Thursday, November 6th. Truist Financial set a $41.00 target price on Viridian Therapeutics in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.90.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.